Skip to content
value.today

Hyperion Therapeutics Inc.

Total raised
$60 M
4 rounds on record
Latest round
$8 M
Oct 2011
First round on record
Aug 2008
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Hyperion Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2014$8 MIssued in a merger or acquisition$2 to $10 million

Hyperion Therapeutics Inc.: Private sale, Jun 2014

Investors in this round

0 investors had bought by the notice of Jun 18, 2014: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Hyperion Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ashley A. Gould · Executive Officer
  • Bruce F. Scharschmidt · Executive Officer
  • Christine A. Nash · Executive Officer
  • Donald J. Santel · Executive Officer
  • Jeffrey S. Farrow · Executive Officer
  • Klara A. Dickinson · Executive Officer
  • Natalie A. Holles · Executive Officer
  • Bijan R. Salehizadeh · Director
  • Bo Jesper I. Hansen · Director
  • Daniel G. Welch · Director
  • Jake R. Nunn · Director
  • James I. Healy · Director
  • Lota S. Zoth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey S. Farrow, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 18, 2014. Read the notice at the SEC.

equitySEC
Oct 2011$8 MNo. 4$2 to $10 million

Hyperion Therapeutics Inc.: Raise no. 4, Oct 2011

Investors in this round

10 investors had bought by the notice of Nov 4, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Hyperion Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $15 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory Notes and Preferred Stock Warrants (incl. (i) the Preferred Stock issuable upon conversion of Notes, (ii) the Preferred Stock issuable upon exercise of Warrants and (iii) the Common Stock i
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce Scharschmidt · Executive Officer
  • Christine Nash · Executive Officer
  • Donald Santel · Executive Officer, Director
  • Jeffrey Farrow · Executive Officer
  • Klara Dickinson · Executive Officer
  • Bijan Salehizadeh · Director
  • Bo Jesper Hansen · Director
  • David Gryska · Director
  • Gaurav Aggarwal · Director
  • Jake Nunn · Director
  • James Healy · Director
  • Lota Zoth · Director
  • Robert Hopfner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey S. Farrow, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 4, 2011. Read the notice at the SEC.

equity, debt, optionsSEC
Apr 2011$17 MNo. 3$10 to $50 million

Hyperion Therapeutics Inc.: Raise no. 3, Apr 2011

Investors in this round

10 investors had bought by the notice of Apr 18, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Hyperion Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $35 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissory Notes and Common Stock Warrants (incl. (i) the Preferred Stock issuable upon conversion of Notes, (ii) the Common Stock issuable upon exercise of Warrants and (iii) the Common Stock issuabl
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce Scharschmidt · Executive Officer
  • Christine Nash · Executive Officer
  • Dion Coakley · Executive Officer
  • Donald Santel · Executive Officer, Director
  • Jeffrey Farrow · Executive Officer
  • Klara Dickinson · Executive Officer
  • Masoud Mokhtarani · Executive Officer
  • Bijan Salehizadeh · Director
  • David Gryska · Director
  • Gaurav Aggarwal · Director
  • Jake Nunn · Director
  • James Healy · Director
  • Lota Zoth · Director
  • Rob Hopfner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Corporate Secretary. Source: SEC Form D, newest notice filed Apr 18, 2011. Read the notice at the SEC.

equity, debt, optionsSEC
Jun 2009$22 MNo. 2$10 to $50 million

Hyperion Therapeutics Inc.: Raise no. 2, Jun 2009

Investors in this round

9 investors had bought by the notice of Jul 16, 2009: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Hyperion Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $45 M offered; $23 M still to sell
Smallest investment taken
$64,214
What was sold
equity, other: Series C-2 Preferred Stock; Common Stock issuable upon coversion thereof
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce Scharschmidt · Executive Officer
  • Christine Nash · Executive Officer
  • Donald Santel · Executive Officer, Director
  • Klara Dickinson · Executive Officer
  • Masoud Mokhtarani · Executive Officer
  • Toni Martinez · Executive Officer
  • Bijan Salehizadeh · Director
  • Daniel Perez · Director
  • Gaurav Aggarwal · Director
  • Jake Nunn · Director
  • Jim Healy · Director
  • Lota Zoth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 16, 2009. Read the notice at the SEC.

equitySEC
Aug 2008$13 MNo. 1$10 to $50 million

Hyperion Therapeutics Inc.: Raise no. 1, Aug 2008

Investors in this round

12 investors had bought by the notice of May 14, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Hyperion Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $15 M offered; $2 M still to sell
Smallest investment taken
$742
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in De

People named in the notice

  • Bruce Scharschmidt · Executive Officer
  • Christine Nash · Executive Officer
  • Don Santel · Executive Officer
  • Klara Dickinson · Executive Officer
  • Masoud Mokhtarani · Executive Officer
  • Toni Martinez · Executive Officer
  • Bijan Salehizadeh · Director
  • Jake Nunn · Director
  • Jim Healy · Director
  • Lota Zoth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed May 14, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hyperion Therapeutics Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Jun 2014).

    SEC Form D (revenue range) · Jun 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Hyperion Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Bay City Capital Fund V Co-Investment Fund, L.P.Fund or asset managernot statednot statedHeld Series C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Bay City Capital Fund V, L.P.Fund or asset managernot statednot statedHeld Series C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Bay City Capital LLCFund or asset managernot statednot statedHeld Series C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Bay City Capital Management V LLCFund or asset managernot statednot statedHeld Series C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Christine A. NashPersonnot statednot statedHeld Series C-1 preferred stock (Form 3, 2012)SEC Form 3
Highland Capital Partners VII-B L.P.Fund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Highland Capital Partners VII-C LPFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Highland Capital Partners VII LPFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Highland Entrepreneurs Fund VII Limited PartnershipFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Highland Management Partners VII Limited PartnershipFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Highland Management Partners VII, LLCFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Klara DickinsonPersonnot statednot statedHeld Series C-1 preferred stock (Form 3, 2012)SEC Form 3
Nea 12 GP, LLCOthernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
NEA Partners 12, Limited PartnershipFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
New Enterprise Associates 12, Limited PartnershipFund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Panorama Capital, L.P.Fund or asset managernot statednot statedHeld Series C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sofinnova Management VII, L.L.C.Fund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sofinnova Venture Partners VII L.P.Venture capitalnot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hyperion Therapeutics Inc.
NameRoleNamed in
Ashley A. GouldExecutive officerJun 2014
Bruce F. ScharschmidtExecutive officerJun 2014
Christine A. NashExecutive officerJun 2014
Donald J. SantelExecutive officerJun 2014
Jeffrey S. FarrowExecutive officerJun 2014
Klara A. DickinsonExecutive officerJun 2014
Natalie A. HollesExecutive officerJun 2014
Bruce ScharschmidtExecutive officerNov 2011
Christine NashExecutive officerNov 2011
Donald SantelExecutive officerNov 2011
Jeffrey FarrowExecutive officerNov 2011
Klara DickinsonExecutive officerNov 2011
Dion CoakleyExecutive officerApr 2011
Masoud MokhtaraniExecutive officerApr 2011
Toni MartinezExecutive officerJul 2009
Don SantelExecutive officerMay 2009
Bijan R. SalehizadehDirectorJun 2014
Bo Jesper I. HansenDirectorJun 2014
Daniel G. WelchDirectorJun 2014
Jake R. NunnDirectorJun 2014
James I. HealyDirectorJun 2014
Lota S. ZothDirectorJun 2014
Bijan SalehizadehDirectorNov 2011
Bo Jesper HansenDirectorNov 2011
David GryskaDirectorNov 2011
Donald SantelDirectorNov 2011
Gaurav AggarwalDirectorNov 2011
Jake NunnDirectorNov 2011
James HealyDirectorNov 2011
Lota ZothDirectorNov 2011
Robert HopfnerDirectorNov 2011
Rob HopfnerDirectorApr 2011
Daniel PerezDirectorJul 2009
Jim HealyDirectorJul 2009